Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Mark Roschewski, Christopher Melani, Rahul Lakhotia, Tatyana Gavrilova, Jagan R. Muppidi, James D. Phelan, Michail S. Lionakis, Kieron Dunleavy, Lode J. Swinnen, Matthias Holdhoff, Catherine E. Lai, Sami Ibrahimi, Michael Glantz, Jan Drappatz, John A. Butman, Stefania Pittaluga, Kim Johnson, Candis Morrison, Nick Micheletti, John D. Heiss, William D. Figg, Elaine S. Jaffe, S. Percy Ivy, Richard Little, Louis M. Staudt, Wyndham H. Wilson
Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Institute of Allergy and Infectious Diseases, Georgetown University, Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, University of Pennsylvania, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Pennsylvania State University, Penn State Milton S. Hershey Medical Center, University of Pittsburgh, UPMC Hillman Cancer Center, National Institutes of Health Clinical Center, National Institute of Neurological Disorders and Stroke
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405038452